Tenaya Therapeutics has received a clinical hold from the FDA for its TN-201 trial, requiring protocol amendments for better patient monitoring, following an independent board's review in summer 2025. The company reports no new safety issues and aims to resolve the hold quickly without major impacts on development timelines.